Occidental Asset Management LLC Takes $4.38 Million Position in Gilead Sciences, Inc. $GILD

Occidental Asset Management LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, HoldingsChannel reports. The firm purchased 34,701 shares of the biopharmaceutical company’s stock, valued at approximately $4,384,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $25,000. Persistent Asset Partners Ltd bought a new stake in Gilead Sciences in the second quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its position in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $26,000. Finally, Wealth Preservation Advisors LLC raised its holdings in Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider owned 124,234 shares of the company’s stock, valued at $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 51,000 shares of company stock worth $6,568,860. 0.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. HSBC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Truist Financial lowered their target price on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research report on Wednesday, May 20th. Finally, Rothschild & Co Redburn decreased their price target on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Twenty-four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $158.04.

Gilead Sciences Stock Up 0.4%

GILD stock opened at $138.92 on Tuesday. The stock’s 50 day simple moving average is $130.33 and its 200 day simple moving average is $136.43. The company has a market cap of $172.25 billion, a P/E ratio of -52.03 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.01 earnings per share. On average, research analysts expect that Gilead Sciences, Inc. will post -0.53 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.